Immunic
IMUX | NASDAQ
$7.23
-$0.29 (-3.86%)
At close: Nov 16, 2026, 4:00 PM ET
$7.23
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Immunic Company Profile
Company profile explainedCompany Profile
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Erik Lundgren | Chief Executive Officer & Director |
| Glenn Whaley | Chief Financial Officer |
| Jason Tardio | Chief Operating Officer & President |
| Chitrang Davé | Chief Data & Digital Officer |
| Hella Kohlhof | Co-Founder & Chief Scientific Officer |
| Inderpal Singh | General Counsel |
| Jessica Breu | Vice President of Investor Relations & Communications |
| Michael A. Panzara | Chief Medical Officer |
| Patrick Walsh | Chief Business Officer |
| Werner Gladdines | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 01, 2026 | S-8 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 11, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | S-8 | Filing |
Immunic
| Country | United States |
| IPO Date | Apr 17, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Erik Lundgren |
Contact Details
1200 Avenue of the Americas New York City,
New York 10036 United States
Stock Details
| Ticker Symbol | IMUX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001280776 |
| CUSIP Number | 4525EP200 |
| ISIN Number | US4525EP2001 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove IMUX